Clinical Trials › NCT07074886
RecruitingPhase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
Sponsored by Hoffmann-La Roche
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 182
Target enrollment
8
U.S. states
Nov 2025
Start date
Oct 2030
Expected completion
Interventions / Treatments
Ocrelizumab Test FormulationOcrelizumab Reference Formulation
Conditions studied
Multiple Sclerosis
Where this trial is running (9 sites)
Florida2 sites
Maitland · Tampa
California1 site
Carlsbad
Colorado1 site
Fort Collins
Maryland1 site
Baltimore
Massachusetts1 site
Worcester
New York1 site
Syracuse
Tennessee1 site
Knoxville
Washington1 site
Seattle
Participating MS centers on MS Buddy (6)
Swedish Neuroscience Institute MS Center
Seattle, WA
Seattle, WA
Advanced Neurology of Colorado
Fort Collins, CO
Fort Collins, CO
Johns Hopkins Multiple Sclerosis Center
Baltimore, MD
Baltimore, MD
SUNY Upstate Neurology
Syracuse, NY
Syracuse, NY
Hope Neurology, PLLC
Knoxville, TN
Knoxville, TN
USF Multiple Sclerosis Center
Tampa, FL
Tampa, FL
MS centers in Florida
Compare treatment centers near a trial site by center type, providers and trials.
View Florida centersMore Phase 2 trials
Browse all Phase 2 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.